CLASS II Drug recall · Reported 23 Oct 2024 · FDA Enforcement Report

Duloxetine Delayed-Release Capsules, USP, 20mg recalled

Breckenridge Pharmaceutical is recalling Duloxetine Delayed-Release Capsules, USP, 20mg, distributed nationwide in the US. The recall was initiated on 10 Oct 2024 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot #: 220128, Exp. Date 12/2024
NDC51991-746, 51991-747, 51991-748, 51991-750
Quantity recalled7,107 bottles

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0009-2025
FDA event ID
95508
Recalling firm
Breckenridge Pharmaceutical, Berlin, CT
Manufacturer
Breckenridge Pharmaceutical, Inc.
Classification
Class II
Status
Completed
Recall initiated
10 Oct 2024
FDA classified
11 Oct 2024
Reported
23 Oct 2024
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Nitrosamine Impurity
Drug class
Antidepressants

Timeline

10 Oct 2024Recall initiated by company
11 Oct 2024Classified by FDA+1 day
23 Oct 2024Published in enforcement report+12 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

Nitrosamines are impurities that can form during drug manufacturing or storage. Above the FDA acceptable intake limit, long-term exposure may raise cancer risk. The FDA advises patients to keep taking the medicine until they have a replacement.

Product as listed by the FDA

Duloxetine Delayed-Release Capsules, USP, 20mg, Rx Only, 500-count bottles, Mfr. by: Towa Pharmaceutical Europe, S.L. Distributed by: BPI, NDC 51991-746-05.

Where it was distributed

Product was distributed nationwide within the United States

Nationwide

Questions about this recall

Why was it recalled?

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

Which lots are affected?

Lot #: 220128, Exp. Date 12/2024

Where was it sold?

Product was distributed nationwide within the United States

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Breckenridge Pharmaceutical

All 35

Other Duloxetine recalls

All 57